Reuters — Canadian cannabis company Aphria said Thursday it was exploring “strategic alternatives,” including a sale, for its U.S. business, amid tightening enforcement of federal cannabis laws in the country.
Earlier this year, the U.S. Department of Justice revoked an Obama administration policy that discouraged federal prosecutors from pursuing marijuana-related crimes in states that had legalized the drug.
While states such as Colorado and California have legalized marijuana, there is sill a federal ban in place. Canada is expected to legalize pot in July.
Read Also
Most of Manitoba harvest wraps up for 2025
Manitoba Agriculture issued its final crop report of 2025, showing the overall provincewide harvest at 97 per cent complete as of Oct. 20. Nearly all major crops have finished combining, with 37 per cent of Manitoba’s sunflowers finished, plus 71 per cent of grain corn and small amounts of soybeans and potatoes left to do.
Canadian securities regulators in October asked U.S.-linked marijuana firm to clearly warn investors about the risks, given the ban.
Leamington, Ont.-based Aphria makes and sells medical cannabis and its U.S. operations are in Florida and Arizona.
On Monday, the company offered to buy rival Nuuvera for $826 million, as it bets on a raft of medical cannabis approvals around the world over the coming years.
Aphria said Thursday it will explore and consider the possibility of selling its U.S. assets to “strategic, long-term and committed investors in the cannabis industry.”
— Reporting for Reuters by John Benny in Bangalore. Includes files from AGCanada.com Network staff.
